pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›apitegromab
drug · antibody
save

apitegromab

pre_registrationupdated 6mo ago
by $SRRK Scholar Rock Holding Corp🔗 ChEMBL
community read0 votes

Antibody drug with a maximum clinical stage of Phase 2 (across all indications), with 4 investigational indications.

indications

indications
Obesity

targets

Growth/differentiation factor 8

all catalysts(0)

nothing on the calendar yet

Trials studying apitegromab

  • phase2A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophyrecruitingn=52
  • phase2Phase 2 Study Evaluating Apitegromab for the Treatment of FSHDnot yet recruitingn=60
  • phase2Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obesecompletedn=102
  • phase3Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplamcompletedn=188
  • phase3Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromabactive not recruitingn=238
  • —EAP of Apitegromab for Patients With Spinal Muscular Atrophyavailable

News(9)

  • On the move: 4 rare disease companies hiring now
    Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.
    biospace · 1mo ago
  • FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
    Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.
    biospace · 1mo ago
  • Scholar Rock SMA drug approved by FDA
    Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard t…
    biopharma_dive · 2mo ago
  • Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
    Scholar Rock’s spinal muscular atrophy drug, now to be called Isembyld, was originally rejected in September 2025, when the FDA cited compliance problems at a third-party manufacturer.
    biospace · 2mo ago
  • Scholar Rock gets FDA nod for spinal muscular atrophy drug
    Scholar Rock has won FDA approval for its drug treating a rare muscle-wasting disease, after facing delays due to a troubled manufacturing factory. The injectable drug apitegromab, branded as Isemb…
    endpoints · 2mo ago
  • Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
    Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
    biospace · 3mo ago
  • Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
    Scholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…
    fiercebiotech · 3mo ago
  • Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab
    Scribe writes in $96M IPO: The gene editing biotech expects net proceeds of about $96 million if it prices its Nasdaq listing at $14 per share, the midpoint of the ...
    endpoints · 4mo ago
  • Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
    Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.
    biopharma_dive · 4mo ago
generic
apitegromab
MOA
Growth/differentiation factor 8 inhibitor
indication
Spinal Muscular Atrophy (SMA)
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 31m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?